EDIT News and Press, Editas Medicine Inc. From 05/28/25

2025-05-28 09:50:11 ET More on related stocks: MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition Ginkgo Bioworks: Cost-Cutting Efforts Aren't Enough Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript) Ocugen wins ...

2025-05-25 06:00:00 ET Over the past few years, investors have moved away from somewhat speculative and unprofitable companies to put their money into safer, steadier investments. Editas Medicine (NASDAQ: EDIT) , a gene-editing-focused clinical-stage biotech, is firmly in the specul...

2025-05-20 05:47:34 ET Summary Here's the next batch of weird science stocks that have market darling potential. I’m tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature s...

2025-05-15 19:30:00 ET Explore the exciting world of Editas Medicine (NASDAQ: EDIT) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used ...

2025-05-14 14:17:01 ET Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference May 14, 2025 08:15 PM ET Company Participants Amy Parison - CFO Christi Bernett - SVP of IR Conference Call Participants Alec Stranahan - BofA Securities ...

Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potentially transformative, in vivo a...

Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: ...

In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today shared i...

2025-05-12 16:35:13 ET More on Editas Medicine Editas Medicine: Do The Risks Outweigh The Rewards? Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript) Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (...

Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week Company will also share in vivo preclinical proof of concept to...